Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing
Abstract Aims/Introduction A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings from the summative usability testing process for...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley
2021-06-01
|
| Saila: | Journal of Diabetes Investigation |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1111/jdi.13429 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|